These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 4392071)

  • 1. [Oral antidiabetics. Dose, plasma concentration and effect].
    Ariëns EJ
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():143-76. PubMed ID: 4392071
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of the beta-cytotropic effect of glymidine sodium (glycodiazine), glucagon, and isopropylnoradrenaline in rats].
    Losert W; Loge O; Jahn P
    Arzneimittelforschung; 1973 Sep; 23(9):1251-60. PubMed ID: 4149442
    [No Abstract]   [Full Text] [Related]  

  • 3. [Changes of pharmacokinetics of oral antidiabetics from drug interference and renal insufficiency].
    Berger W; Spring P
    Dtsch Med Wochenschr; 1970 Dec; 95(50):2525-7. PubMed ID: 5488752
    [No Abstract]   [Full Text] [Related]  

  • 4. [Control of ATP levels in stimulated pancreatic B-cells].
    Hellman B; Idahl LA
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():597-611. PubMed ID: 4313347
    [No Abstract]   [Full Text] [Related]  

  • 5. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 6. Acetohexamide: comparison with other sulfonylurea compounds in the treatment of diabetes mellitus.
    BOSHELL BR; WILENSKY AS; BARRETT JC; ALMON JV
    Clin Pharmacol Ther; 1962; 3():750-7. PubMed ID: 14014164
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hypoglycemic sulfonamides].
    Loubatières AL
    Actual Pharmacol (Paris); 1968; 21():173-90. PubMed ID: 4888764
    [No Abstract]   [Full Text] [Related]  

  • 8. The pharmacology of sulfonylureas.
    Skillman TG; Feldman JM
    Am J Med; 1981 Feb; 70(2):361-72. PubMed ID: 6781341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The action of sulfonylureas on the insulin secretion of the perfused rat pancreas].
    Mariani MM
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():256-70. PubMed ID: 5371307
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current views on the mode of action of hypoglycemic sulfonamides].
    Creutzfeldt W
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():201-15. PubMed ID: 4906019
    [No Abstract]   [Full Text] [Related]  

  • 11. [Side-effects of oral antidiabetics].
    Yawata M; Morita T
    Nihon Rinsho; 1968 Jul; 26(7):1627-32. PubMed ID: 4884329
    [No Abstract]   [Full Text] [Related]  

  • 12. Diazoxide and the secretion of insulin.
    Nutr Rev; 1972 Aug; 30(8):194-8. PubMed ID: 4340200
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro secretion of insulin after glucose, sulphonylureas, adrenergic and cholinergic substances studied by isolated perfused rat pancreas.
    Loubatières A; Loubatières-Mariani MM
    Endocrinol Exp; 1974 Jun; 8(2):75-87. PubMed ID: 4209693
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin secretion studied in the perfused rat pancreas. II. Effect of glucose, glucagon, 3'5' adenosine monophosphate, theophylline, imidazole and phenoxybenzamine; their interaction with diazoxide.
    Basabe JC; Lopez NL; Viktora JK; Wolff FW
    Diabetes; 1971 Jul; 20(7):457-66. PubMed ID: 4397560
    [No Abstract]   [Full Text] [Related]  

  • 15. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
    Zhang CL; Katoh M; Shibasaki T; Minami K; Sunaga Y; Takahashi H; Yokoi N; Iwasaki M; Miki T; Seino S
    Science; 2009 Jul; 325(5940):607-10. PubMed ID: 19644119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACTION OF HYPOGLYCEMIC SULFONAMIDES ON THE PRODUCTION OF CO2 BY ADIPOSE TISSUE OF THE RAT EPIDIDYMIS "IN VITRO"].
    MARQUES M; RIETCORREA P
    Folia Endocrinol; 1964 Jun; 17():381-6. PubMed ID: 14210726
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
    Loubatiéres A; Mariani MM
    Actual Physiol Pathol (Paris); 1973; 4():237-66. PubMed ID: 4219256
    [No Abstract]   [Full Text] [Related]  

  • 18. CLINICAL EFFECTS OF A NEW, POTENT, NON-TOXIC SULFONYLUREA (TOLAZAMIDE).
    GRINNELL EH; SKILLMAN TG; BARSE R; MOLLER CL
    Curr Ther Res Clin Exp; 1964 Jul; 6():433-41. PubMed ID: 14203273
    [No Abstract]   [Full Text] [Related]  

  • 19. Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs.
    Tsalkova T; Gribenko AV; Cheng X
    Assay Drug Dev Technol; 2011 Feb; 9(1):88-91. PubMed ID: 21133673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of oral antidiabetic agents (first of two parts).
    Shen SW; Bressler R
    N Engl J Med; 1977 Mar; 296(9):493-7. PubMed ID: 319363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.